CDK4/6 inhibitors for breast cancer on AARP Medicare Rx Preferred from UHC (S5921-397)
Ibrance, Kisqali and Verzenio, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Wisconsin
- Premium
- $113.90/month
- Deductible
- $130.00, doesn't apply to tier 1 and 2
3 of 3 CDK4/6 inhibitors are covered on this plan. All 3 require prior authorization.
- from $6,172.33Tier 5
- from $3,471.01Tier 5
- from $5,760.85Tier 5
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $130.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.